AstronauTx

Executive Summary

AstronauTx is a UK-based biotechnology company pioneering a novel approach to treat Alzheimer's disease and other neurological disorders by pharmacologically enhancing slow wave sleep (SWS) to restore glymphatic flow and reduce neurotoxic protein accumulation. Founded in 2018 and privately held, the company leverages its deep understanding of sleep architecture to develop small-molecule therapeutics that aim to improve glymphatic clearance of β-amyloid and tau. Currently in preclinical and early discovery stages, AstronauTx targets a fundamental physiological process—sleep—to address the underlying pathology of neurodegeneration. The company is positioned at the intersection of sleep science and Alzheimer's research, an area gaining increasing attention as clinical evidence links sleep disruption to disease progression. With its venture-backed status and a focused pipeline, AstronauTx represents an early-stage opportunity in the neurodegenerative disease space, though it faces significant technical and regulatory hurdles typical of CNS drug development.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Alzheimer's Models30% success
• Q3 2026Series A Financing Announcement60% success
• Q4 2026Key Research Collaboration or Licensing Deal40% success